Esteban Burrone

Public health, innovation, access. Head of Policy, Strategy and Market Access at Medicines Patent Pool (tweets in personal capacity). Retweets not endorsements.

[MedicinesPatentPool @MedsPatentPool]

Today at #WHA79, MPP and @Roche celebrated the signing of a public health-oriented voluntary licence agreement for baloxavir marboxil, an #influenza antiviral treatment recommended by @WHO.
The agreement aims to expand access to baloxavir marboxil in 129 low- and middle-income countries and support broader pandemic preparedness efforts through geographically diversified manufacturing and supply pathways.
This collaboration reflects a shared commitment to strengthening preparedness for future influenza outbreaks and pandemics through innovation, partnership and sustainable access.
Read the announcement: https://t.co/egLNSlK3WR
@Unitaid @DrDuneton @aggrealuso
#GlobalHealthSecurity #AccessToMedicines #GlobalHealth #PublicHealth #PandemicPreparedness

[Esteban Burrone @eburrone]

ViiV and MPP extend voluntary licensing agreement to enable access to long-acting injectable HIV treatment https://t.co/EC9Mmctbsz

[CML AdvocatesNetwork @cmlnet]

📢 Exciting News in Cancer Treatment Access!

The Medicines Patent Pool (MPP), ATOM Coalition, IDA Foundation, and The Max Foundation are thrilled to announce that MPP sublicensee Hetero has received FDA approval for its generic version of nilotinib, a vital medication for #CML.

This milestone marks a significant advancement in making essential cancer treatments more accessible in low- and middle-income countries.

Learn more about this development and its impact on global health: https://t.co/uTURnxuxi9

#CancerTreatment #GlobalHealth #AccessToMedicines #CML #MedicinesPatentPool

[Unitaid @UNITAID]

"Tools on their own don't end epidemics," says @eburrone from the @MedsPatentPool at #AIDS2024. Long-acting PrEP could significantly reduce the 1.3 million new HIV infections yearly, but we need millions on PrEP.

[MedicinesPatentPool @MedsPatentPool]

🎙️@eburrone du MPP au stand de la 🇫🇷

Le programme de transfert de technologies à ARNm a été créé par @WHO et le MPP avec le soutien de la #France 🇫🇷 et d’autres pays suite à l’épidémie de #COVID19 afin d’améliorer la santé et la sécurité sanitaire en développant pour le long terme les capacités de fabrication locales de la technologie à ARNm dans et pour les pays à revenus faible et intermédiaire.

#AIDS2024

https://t.co/wnSYiLIEWG

[Unitaid @UNITAID]

Esteban Burrone (@eburrone) du @MedsPatentPool rappelle que malgré les progrès réalisés, comme le dolutégravir coûtant aussi peu que 40 $ par an, il reste encore beaucoup à faire pour garantir un accès universel aux médicaments contre le VIH. #AIDS2024

[MedicinesPatentPool @MedsPatentPool]

🎙️@eburrone du MPP explique que le MPP contribue à la réponse contre l’épidémie du VIH/sida en accélérant l’accès aux médicaments essentiels dans les pays à revenu faible et intermédiaire en négociant des licences volontaires avec les laboratoires innovants ce qui permet ensuite de fabriquer ces médicaments en version générique pour les personnes qui en ont besoin dans les pays en développement.

#AIDS2024

[Unitaid @UNITAID]

At #AIDS2024, Esteban Burrone (@eburrone) from the @MedsPatentPool highlights that DTG-based regimens are now more affordable at $40 per patient per year, benefiting 24 million people globally and contributing to reduced carbon emissions.

[MedicinesPatentPool @MedsPatentPool]

🎙️@eburrone of MPP concludes the MPP/@UNITAID session at #AIDS2024 by highlighting 3️⃣important lessons we can learn from the DTG story 👇🏼
✅we need to have a parallel approach, and not do things sequentially;
✅in doing so, we need to be ready to take risks;
✅we need to be telling the DTG story to show that accelerated access to innovative medicines is possible, and that we can do it in other disease areas.

[Unitaid @UNITAID]

Early engagement between @MedsPatentPool and innovators, sometimes even before regulatory approval, helps fast-track generic development. This approach has been effective for HIV and COVID treatments, ensuring generics are ready as guidelines evolve, said @eburrone at #AIDS2024.

[MedicinesPatentPool @MedsPatentPool]

#Publication📰 | Our latest article "Intellectual Property Licensing of Therapeutics During the #COVID19 Crisis: Lessons Learnt for #PandemicPreparedness and Response" published in @GHJournal is out! This paper highlights the role of voluntary licensing in facilitating access to COVID-19 therapeutics in #LMICs.

Dive into the full paper for a comprehensive understanding of the lessons learned and recommendations for preparedness and response to future pandemics 👉https://t.co/9LB96XpT7U

#GlobalHealth #PublicHealth #IntellectualProperty #COVID19Response

@TiwaBraimoh @eburrone @CharlieGore @pushpa_sathguru

[GNP+ @gnpplus]

Register and join @gnpplus and @teampata on 4 July for the #BetterMeds4Kids Children’s Access to Life-saving HIV Treatment webinar! Learn about the new #pALD dispersible tablet, a game-changer in children's HIV treatment. @GAP_f_Network

Date: Thursday, 4 July, 2024
Time: 15:00-16:00 SAST/CET

Registration link: https://t.co/QKGFxMGNTl

[MedicinesPatentPool @MedsPatentPool]

Following the MPP-ViiV agreement on #dolutegravir in late 2020, we're pleased to announce progress in the fight against #HIV in Azerbaijan🇦🇿, Belarus🇧🇾, Kazakhstan🇰🇿 & Malaysia🇲🇾👇

✅ In Belarus & Kazakhstan, the volumes of DTG procured by national HIV programmes can cover 78% and 86% of people on #ART respectively.
✅ Azerbaijan is making strides to reach 65%of people on ART with DTG treatments this year🎉
✅Malaysia is planning to accelerate the transition to TLD starting from 2025.

These achievements were made possible by price reductions ↘️  of over 90% and are a result of the dedication of many, incl communities, healthcare professionals & governments.

Read our statement 👉 https://t.co/K4WGMquPSq
#GlobalHealth #Access2Meds

[Esteban Burrone @eburrone]

When I started working in HIV, @MSF’s Untangling the Web was the first publication I was told to read to understand some of the access challenges being faced in LMICs. The breadth of expertise in the AC team has always been impressive. I’m concerned to hear latest developments…

[Esteban Burrone @eburrone]

Very disappointed to have missed the #G20 Health Working Group meeting this week. I tested positive for COVID at the airport as I was about to go through security. A reminder that COVID-19 is far from over....

[MedicinesPatentPool @MedsPatentPool]

🎤@eburrone of MPP closes the session by highlighting 3️⃣ key moments of the #dolutegravir story:
✅ the signing of the licence with ViiV Healthcare in 2014.
✅ when TLD was approved in August 2017. This new fixed-dose combination regimen was created by generic manufacturers thanks to the licence agreement.
✅ when it became real in 2018: people had finally access to DTG 💪🏽💪🏽.

#WHA77 #globalhealth #publichealth

[Esteban Burrone @eburrone]

Looking forward to working closely with Indonesia to facilitate access to health products!

[MedicinesPatentPool @MedsPatentPool]

We are thrilled to announce that we have signed a Memorandum of Understanding with the Ministry of Health of #Indonesia 🇮🇩 on the sidelines of #WHA77 to improve access to health products.

Read our statement > https://t.co/J9G0ADIztk

#HealthForAll #Access2Meds #GlobalHealth #PublicHealth

[MedicinesPatentPool @MedsPatentPool]

Attending #WHA77❓ Make sure you register to the following MPP events (in-person 🤝 or/and online 💻 ) 👇

1️⃣/4 Cinema Premiere 🎞 on "The dolutegravir story: A Decade of Access" co-hosted with @UNITAID.
⏰ 🗓 Tuesday 28 May, 18h30-20h, in-person 🤝 (followed by a reception).
📍 Cinema Nord-Sud, Rue de Servette 78, Geneva (transport available from the Palais)
✅ To register 👉 https://t.co/Mcl3UOxOoZ

#PublicHealth #GlobalHealth #Access2Meds #HealthForAll

[World Health Organization (WHO) @WHO]

Noncommunicable diseases like heart disease, cancers, diabetes, chronic respiratory disease were the biggest killers, accounting for 3/4 of all deaths.

During the #COVID19 pandemic, these diseases caused 78% of non-COVID deaths.

📊  https://t.co/mQj9P65Upb

[MedicinesPatentPool @MedsPatentPool]

🗞️#PressRelease | 🎉The Medicines Patent Pool Unveils New Version🚀 of #MedsPaL 💻for Streamlined Access to #GlobalHealth #IntellectualProperty Information.

Access our PR 👉🏾https://t.co/31gobEtJhx

🔎#MedsPaL is a free resource that provides crucial information on the intellectual property status of
✅patented essential medicines,
✅COVID-19 vaccines, and
✅long-acting platform technologies,
with a particular focus on low- and middle-income countries🌍.